RADNOR, PA / ACCESSWIRE / September 10, 2018 / Kaskela Law LLC is investigating Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (KERX) on behalf of the Company's stockholders.
In 2017, a shareholder class action complaint was filed against the Company in federal court on behalf of certain purchasers of Keryx's common stock. Among other things, the shareholder complaint alleged that Keryx and certain of the Company's senior executive officers violated the federal securities laws by making a series of materially false and misleading statements to investors concerning the Company's relationship with third-party contract manufacturers. Recently the federal court presiding over the litigation denied defendants' motion to dismiss the class action complaint, paving the way for litigation to proceed against Keryx and certain senior executive officer defendants.
Kaskela Law LLC is investigating whether the members of Keryx's Board of Directors failed to properly fulfill their fiduciary duties to the Company and its stockholders in connection with the above.
Current Keryx stockholders who would like more information about their rights and potential remedies are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740, or via email at firstname.lastname@example.org. Additional information about this investigation may also be found online at http://kaskelalaw.com/case/keryx/.
Kaskela Law LLC exclusively represents investors in state and federal actions throughout the country and seeks to drive corporate governance reform at publicly traded companies. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.
SOURCE: Kaskela Law LLC